Compare GRC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | EVO |
|---|---|---|
| Founded | 1933 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | GRC | EVO |
|---|---|---|
| Price | $52.01 | $3.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 68.9K | ★ 73.1K |
| Earning Date | 02-06-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | ★ 31.51 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | $678,522,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $4.94 | N/A |
| Revenue Next Year | $4.02 | $8.52 |
| P/E Ratio | $28.14 | ★ N/A |
| Revenue Growth | ★ 3.19 | N/A |
| 52 Week Low | $30.87 | $2.84 |
| 52 Week High | $54.26 | $4.80 |
| Indicator | GRC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 58.06 |
| Support Level | $51.55 | $3.39 |
| Resistance Level | $54.26 | $3.63 |
| Average True Range (ATR) | 1.44 | 0.09 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 63.15 | 66.23 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.